ClinicalTrials.gg
CompletedNCT05147805Updated Mar 30, 2026

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

A Phase 2 interventional study of Treprostinil Palmitil and Placebo in Pulmonary Arterial Hypertension, sponsored by Insmed Incorporated. Completed at 92 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Insmed Incorporated · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 7 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Mar 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 312 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.

Enrollment
68th of 253
102 · median 40
Started
2022
with 11 others
Phase 2
82 of 312
11 open now
Registered
258th of 312
by date

Among the 312 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 68th largest by enrollment of the 253 interventional ones that give a count, is one of 12 that started in 2022, is one of 82 in phase 2, and was the 258th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

38 of the 312 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Pulmonary Arterial Hypertension with a site in United States, or all of them as a file.
02

Study summary

The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Treprostinil Palmitil
  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be ≥ 18 to ≤ 75 years at the time of signing the form (ICF).
  • Participants must have a diagnosis of World Health Organization (WHO) Group 1 Pulmonary Hypertension (PH) [pulmonary arterial hypertension (PAH)] in any of the following subtypes:

    1. Idiopathic
    2. Heritable
    3. Drug/toxin-induced or connective tissue disease (CTD)-associated PAH
    4. Congenital heart disease-related with simple systemic-to-pulmonary shunt at least 1 year following repair.
  • PAH diagnosis for at least 3 months.
  • Participants must be on stable PH therapy consisting of up to 2 medications from the following classes:

    1. Endothelin receptor antagonists (eg, ambrisentan, bosentan, macitentan)
    2. Phosphoesterase type 5 inhibitors (eg, sildenafil, tadalafil)
    3. Guanylate cyclase stimulator (eg, riociguat)
  • No change in PH medications (eg, ambrisentan, bosentan, macitentan, sildenafil, tadalafil, riociguat) or dosage for at least 30 days prior to Screening.
  • No change in long-term diuretic use or dosage for at least 30 days prior to Screening.
  • (BMI) within the range 18.0-37.0 kg/m\^2 (inclusive).
  • Male participants: Male participants who are not sterile and have female partners of , must be using effective from Day 1 to at least 90 days after the last dose of study drug.
  • Female participants: Women must be (defined as no menses for 12 months without an alternative medical cause), surgically sterile, (ie, post-tubal ligation for at least 12 months) or using highly effective contraception methods (ie, methods that alone or in combination achieve \<1% unintended pregnancy rates per year when used consistently and correctly) from Day 1 to at least 90 days after the last dose of study drug.
  • Male participants with pregnant or non-pregnant woman of childbearing potential partner must use a condom in order to avoid potential exposure to embryo/fetus.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.

Exclusion criteria

Exclusion Criteria:

  • History of PH other than idiopathic, hereditary, drug/toxin-induced, repaired simple congenital heart disease, or CTD-associated PAH (eg, complex, congenital heart disease-associated PAH, portal hypertension-associated PAH, PH belonging to Groups 2 through 5).
  • Allergy, or documented or , to TPIP or Treprostinil or mannitol (an of the TPIP formulation).
  • Any known ventricular or supraventricular tachyarrhythmia except for paroxysmal atrial fibrillation and any symptomatic bradycardia.
  • History of heart disease including (LVEF) ≤ 40% or valvular, constrictive, or symptomatic atherosclerotic heart disease (eg, stable angina, myocardial infarction, etc).
  • Participation in a cardio-pulmonary rehabilitation program within 1 month of Screening Visit.
  • Evidence of thromboembolic disease as assessed by ventilation-perfusion (VQ) scan, pulmonary angiography, or pulmonary computed tomography (CT) scan.
  • Active liver disease or hepatic dysfunction.
  • History of infection.
  • Established diagnosis of viral infection, or positive for hepatitis B surface antigen (HBsAg) at the time of Screening.
  • Established diagnosis of viral infection at the time of screening.
  • Active and current symptomatic coronavirus disease 2019 (COVID-19) or previous severe disease and/or hospitalization due to COVID-19.
  • Use of within 30 days of the Screening Visit.
  • Participants with Down's Syndrome.
  • History of abnormal bleeding or bruising.
  • History of solid organ transplantation.
  • Known or suspected immunodeficiency disorder, including history of invasive opportunistic infections (eg, tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency, or prolonged infections suggesting an immune compromised status, as judged by the Investigator.
  • History of alcohol or drug abuse within 6 months prior to Screening.
  • Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements, in particular with 6-minute walk test (eg, angina pectoris, claudication, musculoskeletal disorder, need for walking aids).
  • Participants with current or recent (past 30 days) lower respiratory tract infection.
  • History of in the past 5 years, with exception of completely treated in situ carcinoma of the cervix and completely treated non- squamous or basal cell carcinoma of the skin.
  • Change in PH medication (endothelin receptor agonists, phosphoesterase type 5 inhibitors, and guanylate cyclase stimulators or diuretics) between Screening and Baseline.
  • Have participated in any other interventional clinical studies within 30 days prior to Screening.
  • Current use of cigarettes (as defined by Centers for Disease Control and Prevention) or e-cigarettes.
  • Participants who currently inhale marijuana (recreational or medical).
  • Pregnant or breastfeeding.

Note: Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Treprostinil Palmitil Inhalation Powder

    Participants will be administered TPIP once per day at a starting dose of 80 micrograms (μg). Participants will be up-titrated to the highest tolerated dose for each individual participant of between 80 μg and 640 μg during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks.

    Drug: Treprostinil Palmitil

  • Placebo comparator
    Placebo

    Participants will be administered a placebo matching TPIP once per day for 16 weeks.

    Drug: Placebo

Interventions

  • Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.

    Also known as: INS1009

  • DrugPlacebo

    Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Pulmonary Vascular Resistance at Week 16

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Change from Baseline in 6-Minute Walk Test Distance at Week 5, Week 10 and Week 16

    Time frame: Baseline and Week 5, Week 10 and Week 16

  2. Percent Change from Baseline in 6-Minute Walk Test Distance at Week 5, Week 10 and Week 16

    Time frame: Baseline and Week 5, Week 10 and Week 16

  3. Number of Participants Who Experience a Treatment-emergent Adverse Event (AE)

    Time frame: Day 1 up to Week 20

  4. Number of Participants Who Experience a Clinically Significant Change from Baseline in Clinical Laboratory Evaluations

    Time frame: Baseline to Week 16

  5. Number of Participants Who Experience a Clinically Significant Change from Baseline in Vital Sign Measurements

    Time frame: Baseline to Week 16

  6. Number of Participants Who Experience a Clinically Significant Change from Baseline in Electrocardiogram (ECG) Measurements

    Time frame: Baseline to Week 16

  7. Number of Participants Who Experience a Clinically Significant Change from Baseline in Physical Examinations

    Time frame: Baseline to Week 16

  8. Maximum Plasma Concentration (Cmax) of Treprostinil Palmitil

    Time frame: Day 1, Weeks 2, 3, 5, 10, and 16: Predose and 0.5, 1, 2 ,4 and 6 hours post-dose

  9. Maximum Plasma Concentration (Cmax) of Treprostinil

    Time frame: Day 1, Weeks 2, 3, 5, 10, and 16: Predose and 0.5, 1, 2 ,4 and 6 hours post-dose

  10. Time to Maximum Plasma Concentration (Tmax) of Treprostinil Palmitil

    Time frame: Day 1, Weeks 2, 3, 5, 10, and 16: Predose and 0.5, 1, 2 ,4 and 6 hours post-dose

  11. Time to Maximum Plasma Concentration (Tmax) of Treprostinil

    Time frame: Day 1, Weeks 2, 3, 5, 10, and 16: Predose and 0.5, 1, 2 ,4 and 6 hours post-dose

  12. Area Under the Concentration-time Curve from Time 0 to 24 Hours Post-Dose (AUC24) of Treprostinil Palmitil

    Time frame: Day 1, Weeks 2, 3, 5, 10, and 16: Predose and 0.5, 1, 2 ,4 and 6 hours post-dose

  13. Area Under the Concentration-time Curve from Time 0 to 24 Hours Post-Dose (AUC24) of Treprostinil

    Time frame: Day 1, Weeks 2, 3, 5, 10, and 16: Predose and 0.5, 1, 2 ,4 and 6 hours post-dose

  14. Area Under the Concentration-time Curve from Time 0 to Infinity (AUC∞) of Treprostinil Palmitil

    Time frame: Day 1, Weeks 2, 3, 5, 10, and 16: Predose and 0.5, 1, 2 ,4 and 6 hours post-dose

  15. Area Under the Concentration-time Curve from Time 0 to Infinity (AUC∞) of Treprostinil

    Time frame: Day 1, Weeks 2, 3, 5, 10, and 16: Predose and 0.5, 1, 2 ,4 and 6 hours post-dose

  16. Area Under the Concentration-time Curve from Time 0 to Last Measurable Concentration (AUClast) of Treprostinil Palmitil

    Time frame: Day 1, Weeks 2, 3, 5, 10, and 16: Predose and 0.5, 1, 2 ,4 and 6 hours post-dose

  17. Area Under the Concentration-time Curve from Time 0 to Last Measurable Concentration (AUClast) of Treprostinil

    Time frame: Day 1, Weeks 2, 3, 5, 10, and 16: Predose and 0.5, 1, 2 ,4 and 6 hours post-dose

  18. Apparent Total Clearance (CL/F) of Treprostinil Palmitil

    Time frame: Day 1, Weeks 2, 3, 5, 10, and 16: Predose and 0.5, 1, 2 ,4 and 6 hours post-dose

  19. Apparent Total Clearance (CL/F) of Treprostinil

    Time frame: Day 1, Weeks 2, 3, 5, 10, and 16: Predose and 0.5, 1, 2 ,4 and 6 hours post-dose

  20. Apparent Volume of Distribution After Non-Intravenous Administration (Vd/F) of Treprostinil Palmitil

    Time frame: Day 1, Weeks 2, 3, 5, 10, and 16: Predose and 0.5, 1, 2 ,4 and 6 hours post-dose

  21. Apparent Volume of Distribution After Non-Intravenous Administration (Vd/F) of Treprostinil

    Time frame: Day 1, Weeks 2, 3, 5, 10, and 16: Predose and 0.5, 1, 2 ,4 and 6 hours post-dose

  22. Elimination Half-Life (t1/2) of Treprostinil Palmitil

    Time frame: Day 1, Weeks 2, 3, 5, 10, and 16: Predose and 0.5, 1, 2 ,4 and 6 hours post-dose

  23. Elimination Half-Life (t1/2) of Treprostinil

    Time frame: Day 1, Weeks 2, 3, 5, 10, and 16: Predose and 0.5, 1, 2 ,4 and 6 hours post-dose

  24. Change from Baseline in the Concentration of N-Terminal-Pro Hormone Brain Natriuretic Peptide (NT-proBNP) Levels at Week 5, Week 10 and Week 16

    Time frame: Baseline and Week 5, Week 10 and Week 16 or end of study

07

Study locations

92 sites
  • USA025
    Phoenix, Arizona 85006, United States
  • USA022
    Scottsdale, Arizona 85258, United States
  • USA021
    Tucson, Arizona 85724, United States
  • USA023
    Sacramento, California 95817, United States
  • USA002
    West Hollywood, California 90048, United States
  • USA008
    Gainesville, Florida 32610, United States
  • USA005
    Jacksonville, Florida 32224, United States
  • USA007
    Orlando, Florida 32803, United States
  • USA011
    Tampa, Florida 33601, United States
  • USA010
    Winter Park, Florida 32792-3800, United States
  • USA009
    Atlanta, Georgia 30309, United States
  • USA006
    Chicago, Illinois 60611, United States
  • USA001
    Chicago, Illinois 60612, United States
  • USA013
    Indianapolis, Indiana 46260, United States
  • USA014
    Iowa City, Iowa 52242, United States
  • USA003
    Kansas City, Kansas 66160, United States
  • USA102
    New York, New York 10021, United States
  • USA017
    New York, New York 10032-1559, United States
  • USA016
    Dallas, Texas 75246, United States
  • USA012
    Denison, Texas 75020, United States
  • USA018
    Houston, Texas 77030, United States
  • ARG009
    Quilmes, Buenos Aires B1878GEG, Argentina
  • ARG002
    Rosario, Santa Fe Province S2013DSR, Argentina
  • ARG006
    Rosario, Santa Fe Province S2013KDS, Argentina
  • ARG007
    San Miguel de Tucumán, Tucumán Province T4000AXL, Argentina
  • ARG004
    Córdoba, X5000DCE, Argentina
  • ARG001
    Córdoba, X5000FPQ, Argentina
  • ARG008
    Cuiudad Autónoma de Buenos Aires, C1430EGF, Argentina
  • AUS005
    New Lambton Heights, New South Wales 2305, Australia
  • AUS004
    Milton, Queensland 4064, Australia
  • AUS001
    Woolloongabba, Queensland 4102, Australia
  • AUS003
    Adelaide, South Australia 5000, Australia
  • AUS002
    Hobart, Tasmania 7000, Australia
  • AUT002
    Linz, Upper Austria 4020, Austria
  • AUT001
    Vienna, 1090, Austria
  • BEL003
    Anderlecht, Brussels Capital 1070, Belgium
  • BEL002
    Leuven, Vlaams Brabant 3000, Belgium
  • BEL001
    Liège, 4000, Belgium
  • BRA003
    Belo Horizonte, Minas Gerais 30130, Brazil
  • BRA004
    Belo Horizonte, Minas Gerais 30441-070, Brazil
  • BRA007
    Passo Fundo, Rio Grande do Sul 99010-120, Brazil
  • BRA006
    Porto Alegre, Rio Grande do Sul 90035-003, Brazil
  • BRA002
    Blumenau, Santa Catarina 80440-080, Brazil
  • BRA001
    São Paulo, 05403-000, Brazil
  • DNK001
    Aarhus N, Central Jutland 8200, Denmark
  • GER005
    Heidelberg, Baden-Wurttemberg 69126, Germany
  • GER006
    Dresden, Saxony 01307, Germany
  • GER001
    Halle, Saxony-Anhalt 6120, Germany
  • GER002
    Lübeck, Schleswig-Holstein 23562, Germany
  • GER007
    Berlin, 12683, Germany
  • GER003
    Munich, 80639, Germany
  • ITA003
    Naples, Campania 80131, Italy
  • ITA006
    Milan, Lombardy 20123, Italy
  • ITA005
    Monza, Lombardy 20900, Italy
  • ITA002
    Pavia, Lombardy 27100, Italy
  • ITA001
    Palermo, Sicily 90127, Italy
  • ITA004
    Roma, 00161, Italy
  • JPN005
    Sapporo, Hokkaidô 060-8543, Japan
  • JPN004
    Sapporo, Hokkaidô 060-8648, Japan
  • JPN007
    Kurume-Shi, Hukuoka 830-0011, Japan
  • JPN006
    Tsukuba, Ibaraki 305-8576, Japan
  • JPN001
    Kagoshima, Kagoshima-ken 890-8520, Japan
  • JPN009
    Nagasaki, Nagasaki 852-8501, Japan
  • JPN002
    Okayama, Okayama-ken 701-1154, Japan
  • JPN008
    Shinjuku-Ku, Tokyo 160-8582, Japan
  • JPN003
    Suita-Shi, Ôsaka 564-8565, Japan
  • MYS005
    Alor Star, Kedah 05460, Malaysia
  • MYS002
    Kuantan, Pahang 25200, Malaysia
  • MYS003
    Kajang, Selangor 43000, Malaysia
  • MYS004
    Sungai Buloh, Selangor 47000, Malaysia
  • MEX005
    Lomas de Guevara, Jalisco 44657, Mexico
  • MEX003
    Mexico City, Mexico City 14080, Mexico
  • MEX004
    San Luis Potosí City, 78200, Mexico
  • MEX001
    Sertoma, 64718, Mexico
  • PHL001
    Quezon City, National Capital Region 1100, Philippines
  • PHL002
    Makati City, 1229, Philippines
  • SRB004
    Belgrade, Belgrade 116550, Serbia
  • SRB001
    Belgrade, 11000, Serbia
  • SRB003
    Belgrade, 11000, Serbia
  • ESP006
    Palma de Mallorca, Balearic Islands 07010, Spain
  • ESP001
    Santander, Cantabria 39008, Spain
  • ESP002
    Barcelona, 8025, Spain
  • ESP007
    Las Palmas, 35010, Spain
  • ESP008
    Madrid, 28046, Spain
  • ESP003
    Seville, 41009, Spain
  • ESP004
    Toledo, 45007, Spain
  • CHE002
    Lausanne, Vaud (fr) CH-1011, Switzerland
  • GBR001
    Bath, Avon BA1 3NG, United Kingdom
  • GBR002
    Glasgow, Lanarkshire G81 4HX, United Kingdom
  • GBR006
    London, London, City of W12 0HS, United Kingdom
  • GBR003
    Newcastle upon Tyne, Tyne and Wear NE3 3HD, United Kingdom
  • GBR004
    London, NW3 2Q, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Mar 2025, 31 months.

Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's 31 months is close to that.

Counting every sponsor, half of 51 studies reached it within 44 months; a quarter within 26 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2021
First posted
Dec 7, 2021
StartActual
Aug 24, 2022
Primary completionActual
Mar 27, 2025
CompletionActual
Mar 27, 2025
Results delay requested
Mar 26, 2026
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05147805
Responsible party
Sponsor
First posted
Dec 7, 2021
Start date
Aug 24, 2022
Primary completion
Mar 27, 2025
Completion
Mar 27, 2025
Last update
Mar 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil hexadecyl ester

Start the discussion